182 related articles for article (PubMed ID: 29113244)
1. Impact of the individualization of the first-line chemotherapy for advanced colorectal cancer based on collagen gel droplet-embedded drug sensitivity test.
Ochiai T; Nishimura K; Watanabe T; Kitajima M; Nakatani A; Nagayasu K; Naito S; Sato T; Kishine K; Abe Y; Hara C; Yamada S; Mashiko S; Nagaoka I
Oncol Lett; 2017 Nov; 14(5):6045-6052. PubMed ID: 29113244
[TBL] [Abstract][Full Text] [Related]
2. Individualized chemotherapy for colorectal cancer based on the collagen gel droplet-embedded drug sensitivity test.
Ochiai T; Nishimura K; Watanabe T; Kitajima M; Nakatani A; Inou T; Washio M; Sakuyama N; Sato T; Kishine K; Ochi T; Okubo S; Futagawa S; Mashiko S; Nagaoka I
Oncol Lett; 2012 Oct; 4(4):621-624. PubMed ID: 23205073
[TBL] [Abstract][Full Text] [Related]
3. Leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan as individualized first-line therapy based on a drug sensitivity test.
Ochiai T; Nishimura K; Watanabe T; Kitajima M; Hashiguchi T; Nakatani A; Marusasa T; Muraki A; Nagaoka I; Futagawa S
Exp Ther Med; 2010 Mar; 1(2):325-329. PubMed ID: 22993545
[TBL] [Abstract][Full Text] [Related]
4. Impact of primary tumor location as a predictive factor in patients suffering from colorectal cancer treated with cytotoxic anticancer agents based on the collagen gel droplet-embedded drug sensitivity test.
Ochiai T; Nishimura K; Watanabe T; Kitajima M; Nakatani A; Nagayasu K; Sakuyama N; Sato T; Kishine K; Abe Y; Nagaoka I
Oncol Lett; 2019 Feb; 17(2):1842-1850. PubMed ID: 30675246
[TBL] [Abstract][Full Text] [Related]
5. The evolving role of oxaliplatin in the management of colorectal cancer.
de Gramont A; Schmoll HJ; Cervantes A; Tournigand C
Colorectal Dis; 2003 Nov; 5 Suppl 3():10-9. PubMed ID: 23573556
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
Bidard FC; Tournigand C; André T; Mabro M; Figer A; Cervantes A; Lledo G; Bengrine-Lefevre L; Maindrault-Goebel F; Louvet C; de Gramont A
Ann Oncol; 2009 Jun; 20(6):1042-7. PubMed ID: 19153116
[TBL] [Abstract][Full Text] [Related]
7. Identification of responders/non-responders to 5-fluorouracil based on individual 50% inhibitory area under the concentration curve of 5-fluorouracil obtained with collagen gel droplet-embedded culture-drug sensitivity test in colorectal cancer.
Ochiai T; Nishimura K; Watanabe T; Kitajima M; Nakatani A; Marusasa T; Hashiguchi T; Uchida T; Sakuyama N; Sato T; Kishine K; Futagawa S; Nagaoka I
Oncol Lett; 2011 Mar; 2(2):309-313. PubMed ID: 22866082
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the individual 50% inhibitory area under the concentration curve of 5-fluorouracil based on the collagen gel droplet embedded culture drug sensitivity test in colorectal cancer.
Ochiai T; Nishimura K; Watanabe T; Kitajima M; Tsuji M; Nakatani A; Nakayama N; Marusasa T; Mashiko S; Nagaoka I; Futagawa S
Mol Med Rep; 2009; 2(3):405-9. PubMed ID: 21475842
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of postoperative oxaliplatin- or irinotecan-based chemotherapy after curative resection of synchronous liver metastases from colorectal cancer.
Hsu HC; Chou WC; Shen WC; Wu CE; Chen JS; Liau CT; Lin YC; Yang TS
Anticancer Res; 2013 Aug; 33(8):3317-25. PubMed ID: 23898098
[TBL] [Abstract][Full Text] [Related]
10. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
11. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
Moreau LC; Rajan R; Thirlwell MP; Alcindor T
Anticancer Res; 2013 Apr; 33(4):1765-8. PubMed ID: 23564831
[TBL] [Abstract][Full Text] [Related]
12. In vitro-chemosensitivity test using the collagen gel droplet embedded culture drug test (CD-DST) for malignant pleural mesothelioma: possibility of clinical application.
Higashiyama M; Oda K; Okami J; Maeda J; Kodama K; Takami K; Morinaga K; Takano T; Kobayashi H
Ann Thorac Cardiovasc Surg; 2008 Dec; 14(6):355-62. PubMed ID: 19131921
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
15. Serum iron levels as a new biomarker in chemotherapy with leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan, with or without molecularly-targeted drugs.
Ochiai T; Nishimura K; Watanabe T; Kitajima M; Nakatani A; Inou T; Shibata H; Sato T; Kishine K; Seo S; Okubo S; Futagawa S; Mashiko S; Nagaoka I
Mol Clin Oncol; 2013 Sep; 1(5):805-810. PubMed ID: 24649250
[TBL] [Abstract][Full Text] [Related]
16. FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer.
Aparicio J; Fernandez-Martos C; Vincent JM; Maestu I; Llorca C; Busquier I; Campos JM; Perez-Enguix D; Balcells M
Clin Colorectal Cancer; 2005 Nov; 5(4):263-7. PubMed ID: 16356303
[TBL] [Abstract][Full Text] [Related]
17. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
18. Safety and antitumor activity of arsenic trioxide plus infusional 5-fluorouracil, leucovorin, and irinotecan as second-line chemotherapy for refractory metastatic colorectal cancer: A pilot study from South India.
Lakshmaiah KC; Chaudhuri T; Babu GK; Lokanatha D; Jacob LA; Suresh Babu MC; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(4):631-633. PubMed ID: 30082548
[TBL] [Abstract][Full Text] [Related]
19. FOLFIRI as second-line chemotherapy after failure of FOLFOX4 in advanced colorectal cancer: a Korean single-center experience.
Kim JH; Park SJ; Park MI; Moon W; Kim SE; Ku KH; Song SE; Kim JH
Korean J Gastroenterol; 2014 Jan; 63(1):18-24. PubMed ID: 24463284
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G
Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
